Valiant Laboratories Approves Q2 Financial Results; Demonstrates Performance Across Segments
Valiant Laboratories Limited has approved its Audited Standalone and Consolidated Financial Results for the quarter ending June 30, 2026. The results were reviewed and approved by the Board of Directors following a meeting held on August 10, 2026, with the audit reports issued by Raman S. Shah & Co., Chartered Accountants.The company operates as a single segment entity in the chemicals manufacturing business.
Standalone Financial Results
The standalone financial results reflect the performance for the quarter ended June 30, 2026, and the year-to-date period spanning April 1, 2026, to June 30, 2026. These results were audited in accordance with Indian Accounting Standard 34 (Ind AS-34).Key operational data from the standalone financial statements are detailed below:
| Particulars | Quarter Ended 30-June 2026 | Quarter Ended 31-Mar 2026 | Quarter Ended 30-June 2025 | Year Ended 31-Mar-2026 |
|---|---|---|---|---|
| Income | ||||
| Revenue from Operations | 734,211 | 653,034 | 510,073 | 21,704.25 |
| Other Income | 8,526 | - | - | 21,993.73 |
| Total Income | 742,737 | 6,607.61 | 5,167.85 | - |
| Expenses | ||||
| Cost of Materials consumed | 4,620.87 | - | - | 2,138 |
| Changes in inventories of Finished Goods, WIP & Stock-In-Trade | (22,933) | 218.85 | (44.09) | - |
| Purchases of stock in Trade | 1,161.23 | 247.83 | 47,004 | 1,556.53 |
| Employee benefit expenses | 12,209 | 129.07 | 119.01 | 500.36 |
| Finance Cost | 7.65 | 172 | 733 | - |
| Depreciation and Amortization | 5,467 | 5,212 | 5,141 | 22,619 |
| Other expenses | 41,740 | 534.10 | 35,037 | 175,563 |
| Total Expenses | 615,457 | 613,412 | 492,328 | 21,238.94 |
| Profit Before Tax | 1,272.80 | 47,349 | 24,457 | 754.79 |
| Total Tax expense (Net) | 324.92 | 12,021 | 63.01 | 199.96 |
| Net Profit for the period | 947.88 | 353.28 | 181.56 | 554.82 |
Consolidated Financial Results
The consolidated financial results cover the Holding Company and its subsidiary, Valiant Advanced Sciences Private Limited. These results were also audited by Raman S. Shah & Co., Chartered Accountants, in line with Ind AS-34.Details of the consolidated performance for the quarter ended June 30, 2026, are presented below:
| Particulars | Quarter Ended 30-June 2026 (Audited) | Quarter Ended 31-Mar 2026 (Audited) | Quarter Ended 30-June 2025 (Audited) | Year Ended 31-Mar-2026 |
|---|---|---|---|---|
| Income | ||||
| Revenue from Operations | 11,528.51 | 9,198.18 | 4,682.27 | 23,746.75 |
| Other Income | 86.03 | 17.12 | 65.54 | 23,204 |
| Total Income | 11,614.53 | 9,215.30 | 4,747.81 | 297,879 |
| Expenses | ||||
| Cost of Materials consumed | 623,495 | 684,552 | - | - |
| Purchases of stock in Trade | 1,161.23 | 247.83 | 470.04 | 904.50 (268.39) |
| Changes in inventories of Finished Goods, WIP & Stock-In-Trade | (62,019) | 11,962 | (44.09) | - |
| Employee benefit expenses | 26,005 | 256.38 | 119.63 | 699.82 |
| Finance Cost | 10,665 | 10,111 | 733 | 19,025 |
| Depreciation, Amortization and impairment Expense | 28,611 | 29,270 | 5,326 | 603.98 |
| Other expenses | 1,566.69 | 1,247.44 | 35,052 | 2,691.58 |
| Total Expenses | 8,995.49 | 9,110.62 | 4,502.94 | 23,901.97 |
| Profit Before Tax | 2,619.05 | 168 | 24,457 | - |
| Total Tax expense (Net) | 508.75 | (71.19) | 62.79 | - |
| Net Profit for the period | 2,110.30 | 17,587 | 182.09 | (326.79) |
Audit and Oversight Details
Raman S. Shah & Co., Chartered Accountants, conducted both audits in accordance with relevant auditing standards. The auditors confirmed their independence regarding the financial results of Valiant Laboratories Limited and its subsidiaries.The consolidated financial results reflect that one subsidiary, which has been audited by its independent auditors, reported total assets of Rs 45,491.02 lakhs and total income of Rs. 11,528.51 lakhs for the quarter ended June 30, 2026.
VALIANTLAB Stock Price Movement
Today, Valiant Laboratories Limited saw its shares climb in post-market trading, settling at ₹67.81 after gaining 4.99%. The stock traded amidst moderate activity, recording a volume of 26,353 shares during the period.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: